Cell and Gene Therapy Bioprocessing MarketSize, Share & Forecast 2026–2035
What Is the Cell and Gene Therapy Bioprocessing Market Size?
The global Cell and Gene Therapy Bioprocessing market was valued at USD 5.1 Billion in 2025 and is projected to grow from USD 5.7 Billion in 2026 to USD 14.8 Billion by 2035, at a CAGR of 11.2% from 2026–2035. North America held ~31.4% share (USD 1.6 billion) of the global market in 2025.
The Cell and Gene Therapy Bioprocessing market is expanding from 5.1 USD billion in 2025 to 14.8 USD billion by 2035, reflecting an 11.2% CAGR. Growth is driven by increasing adoption of single-use bioprocessing systems, chemically defined media expansion, and rising demand for autologous and allogeneic cell therapies across biopharmaceutical manufacturing.
Cell and Gene Therapy Bioprocessing Market Key Takeaways
According to Healthcare Industry Insights analysis, consolidation among major bioprocessing suppliers—particularly Thermo Fisher Scientific, Sartorius AG, and Danaher Corporation—continues to shape market dynamics. These three companies collectively control approximately 45% of the global market through integrated portfolios spanning bioreactors, filtration, sensors, and control software, positioning them to capture disproportionate growth as cell and gene therapy manufacturing scales.
What Does the Cell and Gene Therapy Bioprocessing Market Encompass?
The Cell and Gene Therapy Bioprocessing market encompasses specialized manufacturing systems, media formulations, and equipment required to develop and produce cell and gene therapies at clinical and commercial scales. This market includes single-use bioprocessing systems, bioreactors, filtration and separation technologies, and culture media (liquid and solid/semi-solid formats) used across biopharmaceutical manufacturing and contract development and manufacturing organizations. The market serves both cell therapy and gene therapy applications, addressing the growing pipeline of advanced therapies entering clinical development and commercialization.
The market operates within evolving regulatory frameworks that emphasize quality, safety, and consistency in cell and gene therapy manufacturing. Regulatory bodies including the FDA and EMA have established pathways for advanced therapy approval, driving standardization of bioprocessing practices and adoption of single-use technologies that reduce contamination risk and enhance compliance. Market evolution reflects the transition from traditional stainless steel equipment to disposable bioprocessing solutions, supported by cost efficiency gains, accelerated time-to-market, and demonstrated regulatory acceptance of single-use systems for GMP manufacturing.
| Parameter | Value |
|---|---|
| Market Size in 2025 | USD 5.1 Billion |
| Market Size in 2026 | USD 5.7 Billion |
| Revenue Forecast in 2035 | USD 14.8 Billion |
| Growth Rate | CAGR of 11.2% from 2026 to 2035 |
| Analysis period | 2025-2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
Key Emerging Trends in the Cell and Gene Therapy Bioprocessing
Based on research conducted by Healthcare Industry Insights, we found that four structural trends are reshaping product development, sourcing, and stakeholder engagement across the Cell and Gene Therapy Bioprocessing industry.
Growth Drivers, Restraints & Opportunities
The following interactive matrix quantifies the forces shaping the market through 2035, each scored by its estimated impact on the market's CAGR, geographic focus, and timeline. Type in the search box to filter by driver, restraint, or opportunity.
| Factors ▲ | Type | Qualitative Impact | Geographic Focus | Timeline |
|---|---|---|---|---|
| Transition to Single-Use Bioprocessing Systems | DRIVER | +2.8% | Global | 2025-2035 |
| Expansion of Cell and Gene Therapy Clinical Pipelines | DRIVER | +2.3% | North America, Europe, Asia-Pacific | 2025-2035 |
| Adoption of Chemically Defined Media and Animal-Free Workflows | DRIVER | +1.9% | Global | 2025-2035 |
| Process Automation and Digital Infrastructure Implementation | OPPORTUNITY | +2.1% | North America, Europe | 2025-2035 |
| Emerging Market Manufacturing Capacity Expansion | OPPORTUNITY | +1.8% | Asia-Pacific, Latin America | 2027-2035 |
| Vertical Integration and Co-Location Manufacturing Models | OPPORTUNITY | +1.4% | North America, Europe, Asia-Pacific | 2025-2035 |
| Manufacturing Readiness Gap and Supply Chain Constraints | RESTRAINT | -1.6% | Asia-Pacific, Emerging Markets | 2025-2030 |
| Limited Automation and Process Standardization Capabilities | RESTRAINT | -1.2% | Global | 2025-2035 |
Primary Growth Driver
The transition from traditional stainless steel equipment to single-use bioprocessing systems represents the primary growth catalyst, driven by cost efficiency, reduced contamination risks, regulatory compliance advantages, and accelerated time-to-market. Single-use systems enable faster validation, operational agility, and scalable manufacturing without extensive capital investment in facility infrastructure. This shift is particularly pronounced in Asia-Pacific, which commands 27.5% of global single-use bioprocessing systems revenue, reflecting rapid adoption across emerging manufacturing hubs. The technology enables biopharmaceutical companies and contract development organizations to respond quickly to expanding cell and gene therapy pipelines.
Secondary Growth Driver
The expansion of cell and gene therapy clinical pipelines, with over 1,000 products currently in clinical trials, drives sustained demand for specialized bioprocessing capacity and manufacturing infrastructure. Cell therapy segment represents 86.19% of market share, reflecting substantial clinical development activity across multiple therapeutic areas. This pipeline expansion creates consistent demand for bioprocessing systems, chemically defined media, and specialized equipment across biopharmaceutical manufacturing and contract development and manufacturing organizations. Market growth reflects recognition that scalable, cost-effective manufacturing capabilities are essential to commercialize the expanding portfolio of advanced therapies entering clinical development.
Key Market Restraint
Scalable, cost-effective manufacturing remains the most critical business challenge in cell and gene therapy bioprocessing, driven by process complexity, limited automation capabilities, and supply-chain constraints. A significant gap exists between clinical promise and manufacturing readiness, with existing infrastructure, workforce capabilities, and supply chains unable to scale as rapidly as therapy development. This restraint is particularly acute in Asia-Pacific and emerging markets where manufacturing infrastructure remains in early development stages. Addressing this constraint requires substantial investment in process standardization, automation technologies, workforce development, and supply chain optimization to enable consistent, scalable production of cell and gene therapies.
Source: Healthcare Industry Insights Analysis, 2026
Which Application Segments Are Driving the Highest Revenue Growth?
Segment Sizing: By Therapy Type
Within the By Therapy Type category, the Cell Therapy segment held the dominant market share in 2025. Meanwhile, the Gene Therapy segment is anticipated to be the fastest-growing, expanding at a CAGR of 11.6% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2025–2035) |
|---|---|---|---|---|
| Cell Therapy | 4.4 | 4.9 | 12.7 | 11.2% |
| Gene Therapy | 0.70 | 0.78 | 2.1 | 11.6% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By Media Type
Within the By Media Type category, the Liquid Media segment held the dominant market share in 2025. Meanwhile, the Solid/Semi-Solid Media segment is anticipated to be the fastest-growing, expanding at a CAGR of 11.4% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2025–2035) |
|---|---|---|---|---|
| Liquid Media | 3.2 | 3.6 | 9.2 | 11.1% |
| Solid/Semi-Solid Media | 1.9 | 2.1 | 5.6 | 11.4% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By End-Use Application
The Biopharmaceutical Manufacturing segment completely dominates the By End-Use Application category. It held the largest market share in 2025 and is concurrently anticipated to be the fastest-growing segment, expanding at a remarkable CAGR of 11.3% through 2035.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2025–2035) |
|---|---|---|---|---|
| Biopharmaceutical Manufacturing | 3.2 | 3.6 | 9.3 | 11.3% |
| Contract Development and Manufacturing | 1.9 | 2.1 | 5.5 | 11.2% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By Bioprocessing System Type
Within the By Bioprocessing System Type category, the Single-Use Bioprocessing Systems segment held the dominant market share in 2025. Meanwhile, the Filtration and Separation Systems segment is anticipated to be the fastest-growing, expanding at a CAGR of 11.6% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2025–2035) |
|---|---|---|---|---|
| Single-Use Bioprocessing Systems | 2.6 | 2.9 | 7.4 | 11.0% |
| Bioreactors | 1.5 | 1.7 | 4.4 | 11.4% |
| Filtration and Separation Systems | 1.0 | 1.1 | 3.0 | 11.6% |
Source: Healthcare Industry Insights Analysis, 2026
Key Market Segments
The complete segmentation hierarchy used throughout this report. Click a category to view its sub-segments.
Market Size by Region
Growth Opportunities
Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within this market over the forecast period.
Cell Therapy Manufacturing Expansion
Cell Therapy represents the largest segment, valued at USD 4.4 billion in 2025 and projected to reach USD 12.7 billion by 2035 at 11.1% CAGR. This USD 8.3 billion expansion opportunity reflects increasing clinical adoption and commercialization of cell-based therapeutics. Biopharmaceutical manufacturers and contract developers are investing in advanced bioprocessing infrastructure to support growing manufacturing demands, particularly in single-use systems and chemically defined media adoption.
Asia-Pacific Manufacturing Capacity Development
Asia-Pacific emerges as the fastest-growing region at 12.6% CAGR, expanding from USD 1.4 billion in 2025 to USD 4.6 billion by 2035, representing a USD 3.2 billion opportunity. According to Healthcare Industry Insights Analysis, the region commands 31.4% of global single-use bioprocessing systems revenue. Strategic partnerships between regional manufacturers and global companies accelerate technology transfer, creating substantial opportunities for bioprocessing equipment suppliers and service providers.
Integrated Bioprocessing Solutions Integration
Combined Biopharmaceutical Manufacturing and Contract Development and Manufacturing applications represent USD 14.8 billion by 2035 (USD 9.3 billion and USD 5.5 billion respectively). This integrated approach addresses the need for flexible, scalable manufacturing platforms. Single-use bioprocessing systems and filtration technologies are driving this convergence, with single-use systems alone projected to reach USD 7.4 billion by 2035, offering manufacturers operational efficiency and contamination risk reduction.
Investment Opportunities
What are the capital inflow trends?
Capital inflows are accelerating toward single-use bioprocessing infrastructure and cell and gene therapy manufacturing platforms. The disposable cell culture bag market alone is projected to expand from USD 2.8 billion in 2025 to USD 5.6 billion by 2033, according to market analysis, reflecting investor confidence in flexible, contamination-resistant manufacturing technologies. Chemically defined media markets are similarly expanding from USD 3.8 billion to USD 8.6 billion by 2034, demonstrating sustained investment in upstream bioprocessing standardization and regulatory compliance infrastructure.
How is infrastructure investment shaping the market?
Infrastructure investment is fundamentally reshaping bioprocessing economics through adoption of single-use systems and integrated manufacturing platforms. The single-use bioprocessing systems market is expanding from USD 7.2 billion in 2025 to USD 15.8 billion by 2034, according to market research, driven by reduced capital requirements, accelerated validation timelines, and modular scalability. Major manufacturers including Thermo Fisher Scientific, Sartorius AG, and Danaher Corporation are collectively commanding approximately 31.4% of the global market by leveraging integrated product portfolios spanning bioreactors, filtration systems, sensors, and control software, enabling customers to streamline manufacturing workflows.
What are the ESG considerations?
ESG considerations are driving adoption of chemically defined media and single-use bioprocessing systems that eliminate animal-derived components and reduce environmental contamination risks. The shift from traditional stainless steel equipment to disposable bioprocessing solutions reduces water consumption, sterilization waste, and facility footprint requirements. Regulatory agencies including the FDA and EMA have standardized approval pathways for single-use equipment, encouraging broader adoption across contract manufacturing organizations and academic research institutes while supporting sustainable manufacturing practices aligned with environmental and social governance objectives.
SWOT Analysis
Our assessment indicates that the following strengths, weaknesses, opportunities, and threats characterize the competitive position of the Cell and Gene Therapy Bioprocessing heading into 2035.
Access the Full Market Report
38 countries · 20 companies profiled · 10-year forecast with YoY data tables · Free Excel data file included
Regional Outlook
Click a region to explore its key national markets and growth drivers.
North America maintains a substantial position in the cell and gene therapy bioprocessing market, driven by the concentration of large biopharmaceutical companies, contract research organizations, and advanced manufacturing infrastructure. The region benefits from mature regulatory frameworks, high-volume GMP consumption, and significant investment in cell and gene therapy development. The United States leads with established manufacturing capabilities and strong clinical pipeline activity. Grow is supported by increasing adoption of single-use bioprocessing systems and chemically defined media, reducing contamination risk and operational complexity. The region's market expansion reflects rising demand for personalized medicine and regenerative therapies, alongside continuous innovation in bioprocessing technologies.
United States
CanadaEurope represents the second-largest regional market for cell and gene therapy bioprocessing, with strong capabilities in chemically defined media and single-use bioprocessing systems. The region holds approximately 28.3% of global chemically defined media revenue, reflecting established manufacturing standards and regulatory compliance frameworks. Germany, the United Kingdom, and France lead with advanced biopharmaceutical infrastructure and research institutions. Grow is driven by increasing clinical trials, expanding manufacturing capacity, and adoption of advanced bioprocessing technologies. European manufacturers emphasize quality, sustainability, and compliance with stringent regulations, supporting market expansion across cell therapy, gene therapy, and regenerative medicine applications.
Germany
United Kingdom
FranceAsia-Pacific emerges as the fastest-growing regional market for cell and gene therapy bioprocessing, commanding 27.5% of global single-use bioprocessing systems revenue. China, India, Japan, and South Korea drive expansion through increasing manufacturing capacity, rising investment in biotechnology infrastructure, and growing clinical trial activity. The region benefits from cost-effective manufacturing, expanding biopharmaceutical sectors, and government support for cell therapy development. Rapid adoption of advanced bioprocessing technologies, including single-use systems and chemically defined media, reflects modernization of manufacturing practices. Strategic partnerships between regional manufacturers and global companies accelerate technology transfer and market penetration.
China
India
Japan
South KoreaLatin America represents an emerging market for cell and gene therapy bioprocessing, with moderate growth driven by increasing biopharmaceutical investment and expanding manufacturing capabilities. Brazil leads regional development with growing contract manufacturing services and clinical trial infrastructure. The region benefits from cost advantages, expanding healthcare sectors, and rising investment in biotechnology development. Adoption of bioprocessing technologies remains below mature markets but accelerates through partnerships with global manufacturers and technology transfer initiatives. Regulatory frameworks continue to evolve, supporting commercialization of cell and gene therapies. Market expansion reflects growing recognition of regenerative medicine potential and increasing clinical trial activity.
Brazil
ArgentinaMiddle East & Africa represents a nascent market for cell and gene therapy bioprocessing, with limited but expanding manufacturing infrastructure. The United Arab Emirates and Saudi Arabia lead regional development through government-backed biotechnology initiatives and investment in healthcare innovation. Market growth reflects increasing recognition of cell and gene therapy potential and strategic partnerships with global manufacturers. Adoption of advanced bioprocessing technologies remains in early stages but accelerates through technology transfer and capacity building initiatives. Regulatory frameworks continue to develop, supporting commercialization pathways. Regional expansion is supported by growing healthcare expenditure and increasing clinical research activity, though market penetration remains below other regions.
United Arab Emirates
Saudi ArabiaCompetitive Landscape
Cell and Gene Therapy Bioprocessing Competitive Insights
| Dimension | Description |
|---|---|
| Market Concentration | Three major players control approximately 45% of the global market, indicating moderate consolidation with significant opportunities for specialized competitors. |
| Product Differentiation | Companies differentiate through integrated single-use systems, proprietary film technologies, and comprehensive bioreactor and filtration portfolios. |
| Geographic Reach | Major players maintain extensive North American manufacturing and distribution networks, with growing presence in Europe and Asia-Pacific regions. |
| Innovation Focus | Investment in proprietary film technologies, sensor integration, and control software represents key competitive differentiation strategies. |
| M&A Activity | Strategic acquisitions and partnerships focus on expanding bioprocessing capabilities and integrating complementary technologies into broader platform offerings. |
Source: Healthcare Industry Insights Analysis, 2026
Competitive Overview
The cell and gene therapy bioprocessing market exhibits moderate consolidation, with Thermo Fisher Scientific, Sartorius AG, and Danaher Corporation collectively commanding approximately 45% of global market share. These established players leverage integrated product portfolios spanning bioreactors, filtration systems, sensors, and control software. Alongside these major competitors, specialized contract development and manufacturing organizations such as Made Scientific, Lonza Group, and Catalent serve distinct market segments. The competitive landscape remains dynamic, with both consolidation among large players and emergence of focused niche competitors addressing specific therapeutic modalities and manufacturing requirements.
Innovation & Differentiation
Innovation strategies center on proprietary film technologies and single-use system integration, with major players investing significantly in these areas. Companies differentiate through advanced bioreactor designs, enhanced filtration capabilities, and integrated sensor and control software platforms. Specialized CDMOs focus on manufacturing expertise for autologous and allogeneic cell therapies, offering tailored solutions for clinical and commercial supply. Technology integration across the bioprocessing workflow—from cell culture through final product release—represents a critical competitive advantage, enabling customers to streamline operations and reduce manufacturing complexity.
Mergers & Expansion
Strategic M&A activity reflects industry consolidation and capability expansion. Major players pursue acquisitions to strengthen integrated product offerings and expand geographic presence, particularly in North America. Smaller specialized firms seek partnerships with larger organizations to access distribution networks and complementary technologies. Investment in manufacturing infrastructure and distribution networks demonstrates commitment to supporting market growth from 5.1 billion in 2025 to 14.8 billion in 2035. Expansion strategies emphasize both organic grow through innovation and inorganic grow through targeted acquisitions of complementary bioprocessing capabilities.
Key Market Players in the Cell and Gene Therapy Bioprocessing
Key companies active in the global Cell and Gene Therapy Bioprocessing include:
Latest Cell and Gene Therapy Bioprocessing Industry Developments
Recent developments center on integrated end-to-end cell and gene therapy solutions, single-use bioprocessing system adoption, disposable cell culture bag expansion, and chemically defined media standardization. Major players including Thermo Fisher Scientific, Sartorius AG, and Danaher Corporation are advancing proprietary film technologies and sensor-enabled monitoring systems while regulatory bodies standardize approval pathways for single-use equipment.
| Date | Summary | Source |
|---|---|---|
| June 30, 2026 | Market analysis indicates disposable cell culture bags valued at USD 2.8 billion in 2025, expanding to USD 5.6 billion by 2033 at 10.9% CAGR, driven by cell therapy production requiring flexible, contamination-resistant manufacturing platforms. | Official Press Release |
| October 1, 2025 | Thermo Fisher Scientific expanded its integrated cell and gene therapy portfolio spanning discovery through commercial manufacturing, leveraging over 30 years of CGT manufacturing experience and 14 years of viral vector CDMO expertise to support cGMP compliance and supply chain requirements. | Official Press Release |
| October 1, 2025 | Chemically defined media market valued at USD 3.8 billion in 2025, projected to reach USD 8.6 billion by 2034 at 9.5% CAGR, driven by biopharmaceutical manufacturing shift away from animal-derived components and cell and gene therapy pipeline expansion. | Official Press Release |
| August 1, 2025 | Sartorius AG contributed to comprehensive market analysis showing single-use bioprocessing systems valued at USD 7.2 billion in 2025, projected to reach USD 15.8 billion by 2034 at 11.0% CAGR, driven by cell and gene therapy demand and regulatory standardization. | Official Press Release |
Source: Healthcare Industry Insights Analysis, 2026
Key Benefits for Cell and Gene Therapy Bioprocessing Stakeholders
Conclusion and Recommendations
Market Outlook
The Cell and Gene Therapy Bioprocessing market is positioned for substantial expansion, growing from USD 5.1 billion in 2025 to USD 14.8 billion by 2035, representing a USD 9.7 billion opportunity at 11.6% CAGR. North America leads with ~31.4% share (USD 1.60 billion), while Asia-Pacific emerges as the fastest-growing region at 12.6% CAGR, expanding from USD 1.4 billion to USD 4.6 billion. Cell Therapy dominates at USD 12.7 billion by 2035, while Gene Therapy accelerates at 11.6% CAGR. Single-use bioprocessing systems and chemically defined media drive technology adoption across manufacturing applications.
Strategic Recommendations
Stakeholders should prioritize capacity expansion in Asia-Pacific, where manufacturing grow reaches USD 1.4 billion by 2035. Investment in single-use bioprocessing systems and chemically defined media adoption reduces contamination risk and operational costs. Strategic partnerships between global manufacturers and regional developers accelerate technology transfer and market penetration. Biopharmaceutical companies should expand contract manufacturing capabilities to support growing cell and gene therapy pipelines. Equipment suppliers should focus on integrated bioprocessing solutions combining bioreactors, filtration systems, and automation technologies to address scalability demands.
Investment Considerations
The market presents attractive investment opportunities with consistent 11.2% CAGR growth and expanding applications across cell and gene therapies. North America's mature regulatory environment and established manufacturing infrastructure provide stable returns, while Asia-Pacific's 12.6% CAGR growth offers higher expansion potential. Key investment risks include high capital requirements for GMP-certified facilities, regulatory complexity, and supply chain constraints. Technology companies focusing on single-use systems and automation solutions are well-positioned for grow. Long-term value creation depends on successful commercialization of cell and gene therapy pipelines and continued regulatory support.
Growth Pathways
Future growth will be driven by expanding cell therapy manufacturing, with the segment reaching USD 12.7 billion by 2035. Gene Therapy manufacturing at 11.6% CAGR presents accelerating opportunities as clinical pipelines mature. Asia-Pacific manufacturing capacity expansion, growing from USD 1.4 billion to USD 4.6 billion, creates substantial infrastructure investment opportunities. Integrated bioprocessing solutions combining single-use systems, bioreactors, and filtration technologies address scalability challenges. Emerging markets in Latin America and Middle East & Africa offer growth potential, though at slower rates of 8.6% and 11.3% CAGR respectively, requiring strategic partnerships and technology transfer initiatives.
Frequently Asked Questions
Summarize This Report:
You May Also Like
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet with your exact requirements. Get 30% free customisation on this report.